Similar Posts
Amarantus Announces the Presentation of Data Showing MANF”s Positive Effect on Retinal Function at Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Amarantus BioScience Holdings, Inc. announced the presentation of positive preclinical data for MANF (mesencephalic-astrocyte-derived neurotrophic factor) in retinitis pigmentosa (RP) at the Association for Research in Vision and Ophthalmology Annual Meeting, being held in Denver, CO. The results from preclinical studies demonstrate that MANF preserves the light-sensing function of photoreceptor cells in a genetic model of…
EyeCRO joins Novo Nordisk, Novartis, Sanofi, Merck KGaA Darmstadt Germany, Lundbeck, and Leo Pharma to prioritize animal welfare in scientific research by signing the Marseille Declaration
“Toward enhancing ethical practices in scientific research, EyeCRO has joined several industry-leading companies to sign the “Marseille Declaration”, the first joint pharmaceutical industry declaration on animal housing and use.” Click here to read the full press release
Aerie Pharmaceuticals Announces Potential Breakthroughs with New Preclinical Research
Aerie Pharmaceuticals, Inc. (AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today potentially breakthrough findings from new preclinical research. The research found that RhopressaTM suppressed the activity of profibrotic proteins – TGF-beta 2 and…
Double-Barreled Biologic for Diabetic Retinopathy Emerging
CHICAGO — Investigators searching for new ways to manage diabetic macular edema are targeting pathways beyond vascular endothelial growth factor (VEGF). Phase 2 results from the BOULEVARD trial (NCT02699450), which is comparing faricimab, the first biologic to target both the Ang-2 and VEGF pathways, with ranibizumab, will be presented at the American Society of Retina Specialists (ASRS) 2019 Annual…
Telemedicine Doubles Screening Rates for Retinopathy
The use of telemedicine helped a primary care clinic more than double the percentage of diabetic patients undergoing screening for retinopathy over the course of a year, according to a research letter published this month in the Archives of Internal Medicine. The researchers, based out of the University of North Carolina at Chapel Hill,…
Adolescents with Diabetes Experiencing Decrease in Retinopathy
A long-term study from Australia has claimed that there has been a significant reduction in the number of cases of retinopathy among young patients with type 1 diabetes who have had intensive glycaemic control therapy. http://www.diabetes.co.uk/news/2011/Oct/adolescents-with-diabetes-experiencing-decrease-in-retinopathy-95087803.html